Adhera Therapeutics, Inc. (ATRX)

Adhera Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
Revenue	0	0	0	0	0.25	0.08
Revenue Growth (YoY)	-	-	-	-	230.77%	-
Cost of Revenue	0	0	0	0	0.41	0.46
Gross Profit	0	0	0	0	-0.16	-0.38
Selling, General & Admin	1.28	1.62	0.67	2.04	9.97	9.67
Research & Development	0	0	0	0	0	0.24
Other Operating Expenses	0.14	0	-0.14	0.05	0.07	-0.81
Operating Expenses	1.28	1.62	0.67	2.04	10.04	10.24
Operating Income	-1.28	-1.62	-0.67	-2.04	-11.32	-15.79
Interest Income	0	0	0	0	0	0
Interest Expense	3.2	3.15	1.43	1.77	0.66	0.15
Other Expense / Income	-2.15	-2.65	4.25	-0.04	0	-4.37
Pretax Income	-4.13	-2.11	-6.35	-3.77	-11.98	-16.75
Income Tax	0.21	-4.47	1.43	1.77	0.66	5.18
Net Income	-2.53	2.35	-7.78	-5.54	-12.64	-16.75
Shares Outstanding (Basic)	4	2	1	1	1	1
Shares Outstanding (Diluted)	4	2	1	1	1	1
Shares Change	36.16%	254.91%	19.56%	0.33%	0.02%	10.19%
EPS (Basic)	-0.52	1.02	-11.97	-10.19	-23.32	-30.92
EPS (Diluted)	-0.60	1.02	-11.97	-10.19	-23.32	-30.92
Free Cash Flow	-0.81	-1.42	-0.67	-0.59	-8.74	-9.69
Free Cash Flow Per Share	-0.19	-0.61	-1.02	-1.08	-16.12	-17.87
Gross Margin	-	-	-	-	-62.30%	-502.09%
Operating Margin	-	-	-	-	-4490.48%	-20731.94%
Profit Margin	-	-	-	-	-5015.87%	-21992.17%
Free Cash Flow Margin	-	-	-	-	-3467.46%	-12713.36%
EBITDA	-1.74	-1.62	-0.82	-1.99	-10.12	-11.1
EBITDA Margin	-	-	-	-	-4015.08%	-14564.82%
Depreciation & Amortization	1.64	1.81	0.4	0.4	0.08	0.33
EBIT	-3.38	-3.43	-1.21	-2.39	-10.2	-11.43
EBIT Margin	-	-	-	-	-4047.62%	-15001.89%

Sources: The data provider is Financial Modeling Prep and the numbers are sourced from SEC filings.